% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{WitzensHarig:127803,
      author       = {M. Witzens-Harig and A. Benner$^*$ and F. McClanahan and J.
                      Klemmer and J. Brandt and E. Brants and M. Rieger and J.
                      Meissner and M. Hensel and K. Neben$^*$ and P. Dreger and E.
                      Lengfelder and I. Schmidt-Wolf and A. Krämer$^*$ and A. D.
                      Ho},
      title        = {{R}ituximab maintenance improves survival in male patients
                      with diffuse large {B}-cell lymphoma. {R}esults of the
                      {HD}2002 prospective multicentre randomized phase {III}
                      trial.},
      journal      = {British journal of haematology},
      volume       = {171},
      number       = {5},
      issn         = {0007-1048},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell55962},
      reportid     = {DKFZ-2017-03825},
      pages        = {710 - 719},
      year         = {2015},
      abstract     = {In the multicentre prospective randomized HD2002 trial,
                      rituximab maintenance therapy (375 mg/m(2) every 3 months
                      for 2 years) versus observation was evaluated for CD20(+)
                      B-cell lymphoma. Out of 321 patients [161 randomized to the
                      treatment group (TG), 160 to the observation group (OG)],
                      295 data sets were evaluable for statistical analysis.
                      Estimated 5-year relapse-free survival (RFS) was $81\%$ in
                      the TG and $70\%$ in the OG (logrank test, P = 0·047). In
                      the diffuse large B-cell lymphoma (DLBCL) subgroup (n =
                      152), 5-year RFS was excellent, at $87\%$ in the TG and
                      $84\%$ in the OG (logrank test, P = 0·35). Of note, only in
                      male patients of the DLBCL subgroup was RFS significantly
                      superior in the TG in comparison to the OG (5-year RFS:
                      $88\%$ vs. $74\%;$ logrank test, P = 0·05). Cox regression
                      analysis showed a significant interaction between treatment
                      and gender regarding overall survival (OS) (P = 0·006) and
                      RFS (P = 0·02), with a lower hazard in females than males
                      in the OG [OS: hazard ratio (HR) (female:male) = 0·11;
                      $95\%$ confidence interval (CI) = 0·00-1·03; RFS: HR
                      (female:male) = 0·27; $95\%$ CI = 0·05-0·97], and no
                      significant differences between males and females in the TG.
                      We conclude that Rituximab maintenance therapy improves
                      survival in male patients with DLBCL.},
      keywords     = {Antineoplastic Agents (NLM Chemicals) / Rituximab (NLM
                      Chemicals)},
      cin          = {C060 / G330},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G330-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26449739},
      doi          = {10.1111/bjh.13652},
      url          = {https://inrepo02.dkfz.de/record/127803},
}